Divi's Laboratories Ltd.

₹7,330

12 (0.2%)

DIVISLAB Share Price

Pharmaceuticals & Biotechnology

As on July 21, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 1,96,137 Cr

P/E Ratio75.64

Dividend Yield0.2 %

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	7,296.9	Bullish
10-DMA	7,101.55	Bullish
20-DMA	6,899	Bullish
50-DMA	6,790.91	Bullish
100-DMA	6,519.31	Bullish
200-DMA	6,434.27	Bullish

Historical Performance

1 Year

9.6%

3 Years

98.7%

5 Years

53.1%

10 Years

517.1%

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Net Sales	1,05,600	93,600	78,450	77,670	89,598
Total Expenditure	71,180	63,930	56,390	53,980	50,787
Other Income	5,070	3,540	3,390	3,450	1,159
Operating Profit	39,490	33,210	25,450	27,140	39,970
Interest	240	30	40	20	20
Depreciation	4,630	4,020	3,780	3,430	3,115
Profit Before Tax	33,880	29,160	21,630	23,690	36,835
Consolidated Net Profit	25,680	21,910	16,000	18,240	29,604
Adjusted EPS	97	83	60	69	112

Compounded Sales Growth

10 Years:22.8

5 Years:8.7

3 Years:6.3

TTM:2.4

Compounded Profit Growth

10 Years:17.9

5 Years:5.3

3 Years:7.1

TTM:3.2

Stock Price CAGR

10 Years:19.8

5 Years:8.6

3 Years:25.7

TTM:10.8

Return on Equity

10 Years:39.9

5 Years:111.5

3 Years:60.4

last year:96.9

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Share Capital	530	530	530	530	531
Total Reserves	1,67,080	1,49,160	1,35,180	1,27,140	1,16,751
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	12,150	5,000	6,110	5,570	4,365
Other Current Liabilities	7,600	4,860	4,040	3,320	3,940
Short Term Borrowings	---	20	---	---	---
Total Liabilities	2,08,780	1,77,170	1,59,370	1,48,630	1,46,191
Capital Work in Progress	21,130	10,220	7,780	2,120	4,699
Long Term Loans & Advances	2,040	3,010	1,760	970	1,337
Currents Investments	---	---	---	---	---
Short Term Loans and Advances	14,610	11,560	7,940	7,150	15,093
Total Current Assets	1,19,550	1,08,770	1,01,520	97,500	96,104
Total Assets	2,08,780	1,77,170	1,59,370	1,48,630	1,46,191
Adjusted Book Value	632	565	512	482	442

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a high PE of 75.64, indicating expensive valuation or elevated growth expectations.
Over the last three years, the stock delivered a strong 3-year price CAGR of 25.8%, indicating sustained price appreciation.
The stock carries a low beta of 0.6, suggesting lower volatility than the broader market.
In the last financial year, the company reported an EBITDA of ₹39490 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹105600 million, indicating a large and established business.

Investment Calculator

Investment Amount:₹

Investment Amount: ₹ 1000000

Current Value: ₹ 1108422.8

No. of Shares: 151 (Approx)

Performance:10.8%

108422.8

NIFTY Performance: -3.5%

1 day Top Gainers